Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Magi Andorra, Ana Freire, Irati Zubizarreta, Nicole Kerlero de Rosbo, Steffan D Bos, Melanie Rinas, Einar A Høgestøl, Sigrid A de Rodez Benavent, Tone Berge, Synne Brune-Ingebretse, Federico Ivaldi, Maria Cellerino, Matteo Pardini, Gemma Vila, Irene Pulido-Valdeolivas, Elena H Martinez-Lapiscina, Sara Llufriu, Albert Saiz, Yolanda Blanco, Eloy Martinez-Heras, Elisabeth Solana, Priscilla Bäcker-Koduah, Janina Behrens, Joseph Kuchling, Susanna Asseyer, Michael Scheel, Claudia Chien, Hanna Zimmermann, Seyedamirhosein Motamedi, Josef Kauer-Bonin, Alex Brandt, Julio Saez-Rodriguez, Leonidas G Alexopoulos, Friedemann Paul, Hanne F Harbo, Hengameh Shams, Jorge Oksenberg, Antonio Uccelli, Ricardo Baeza-Yates, Pablo Villoslada
BACKGROUND: Multiple sclerosis patients would benefit from machine learning algorithms that integrates clinical, imaging and multimodal biomarkers to define the risk of disease activity. METHODS: We have analysed a prospective multi-centric cohort of 322 MS patients and 98 healthy controls from four MS centres, collecting disability scales at baseline and 2 years later. Imaging data included brain MRI and optical coherence tomography, and omics included genotyping, cytomics and phosphoproteomic data from peripheral blood mononuclear cells...
December 22, 2023: Journal of Neurology
#22
JOURNAL ARTICLE
Isabel A Temperley, Alexandra N Seldon, Madeline Aw Reckord, Claudia A Yarad, Farihah T Islam, Kerith Duncanson, Rodney A Lea, Jeannette Lechner-Scott, Vicki E Maltby
BACKGROUND: Many diets promoted specifically for multiple sclerosis have been suggested to improve disease activity. Dairy and gluten are two components for which the recommendations vary between these diets. Existing research into the association between these dietary components and disease activity has been conflicting. OBJECTIVE: To explore the relationship between dairy and gluten intake and disease activity in multiple sclerosis over a 2-year period, using no evidence of disease activity (NEDA) 3 status...
2023: Multiple Sclerosis Journal—Experimental, Translational and Clinical
#23
REVIEW
Ali Msheik, Farah Assi, Faten Hamed, Ali Jibbawi, Anna-Marina Nakhl, Anthony Khoury, Rami Mohanna, Teddy Gerges, Rami Atat
This comprehensive literature review underscores the potential of stem cell transplantation (SCT) as a therapeutic intervention for multiple sclerosis (MS). By amalgamating evidence from various sources, including randomized controlled trials (RCTs), observational, retrospective, and comparative studies, this review offers a holistic understanding of SCT's effectiveness, safety, and feasibility in diverse contexts of MS management. SCT has shown promise in mitigating disease activity and progression, particularly in relapsing-remitting MS (RRMS)...
October 2023: Curēus
#24
JOURNAL ARTICLE
Sena Destan Bunul, Aybala Neslihan Alagoz, Bilge Piri Cinar, Fatih Bunul, Seyma Erdogan, Husnu Efendi
BACKGROUND: Multiple sclerosis (MS) is a disease of the central nervous system characterized by inflammation, demyelination, and axonal degeneration. This study aimed to investigate the relationship between inflammatory indexes and MS disease activity and progression. METHODS: A prospective cohort study was conducted at the Kocaeli University Neurology Clinic, involving 108 patients diagnosed with MS. Data related to patient demographics, clinical presentations, radiological findings, and laboratory results were recorded...
October 26, 2023: Journal of Personalized Medicine
#25
JOURNAL ARTICLE
Tamara Martinovic, Sasenka Vidicevic, Darko Ciric, Vladimir Bumbasirevic, Zeljka Stanojevic, Jelena Tasic, Sasa Petricevic, Aleksandra Isakovic, Vesna Cemerikic Martinovic, Neda Drndarevic, Vladimir Trajkovic, Tamara Kravic-Stevovic
Mott cells are plasma cells that have multiple spherical Russell bodies packed in their cytoplasm. Russell bodies are dilated endoplasmic reticulum cisternae filled with aggregates of immunoglobulins that are neither secreted nor degraded. Mott cells were observed in our study by light and electron microscope in the lymph nodes of rats with experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. Mott cells were detected on hematoxylin and eosin (HE)-stained lymph node sections as vacuolated cells with eccentrically positioned nuclei and large number of faint blue spherical inclusions in the cytoplasm...
November 12, 2023: Histochemistry and Cell Biology
#26
JOURNAL ARTICLE
Mantas Vaisvilas, Gintaras Kaubrys, Rasa Kizlaitiene, Vera Taluntiene, Natasa Giedraitiene
OBJECTIVE: To assess the differences of treatment outcomes regarding disease activity in patients with highly active relapsing multiple sclerosis (RMS), treated with autologous hematopoietic stem cell transplantation (HSCT) or alemtuzumab (ATZ). METHODS: Open-label prospective single-center observational cohort study, enrolling patients with highly active RMS for treatment with ATZ or HSCT between 2014 and 2021. RESULTS: A total of 50 patients (31/50 (62 %) in HSCT vs 19/50 (38 %) in ATZ group) were included...
October 29, 2023: Multiple Sclerosis and related Disorders
#27
RANDOMIZED CONTROLLED TRIAL
Kimia Motlagh Asghari, Neda Dolatkhah, Hormoz Ayromlou, Fatemeh Mirnasiri, Taher Dadfar, Maryam Hashemian
Multiple Sclerosis (MS) is a chronic demyelination disease of the central nervous system (CNS). The gut-brain axis involves communication between the nervous, endocrine, and immune systems. Probiotics can positively impact immune and inflammatory responses by regulating gut microbiota. A total of 40 MS patients (average age of 34.38 ± 6.65) were examined to determine the effect of the Saccharomyces boulardii supplement for four months compared to a placebo. The results showed that the Saccharomyces boulardii significantly decreased the inflammatory marker high-sensitivity C-reactive protein (hs-CRP) compared to the placebo (P < 0...
October 30, 2023: Scientific Reports
#28
JOURNAL ARTICLE
Ignacio Casanova, María I Domínguez-Mozo, Laura De Torres, Yolanda Aladro-Benito, Ángel García-Martínez, Patricia Gómez, Sara Abellán, Esther De Antonio, Roberto Álvarez-Lafuente
MicroRNAs (miRNAs) are promising biomarkers in multiple sclerosis (MS). This study aims to investigate the association between a preselected list of miRNAs in serum with therapeutic response to Glatiramer Acetate (GA) and with the clinical evolution of a cohort of relapsing-remitting MS (RRMS) patients. We conducted a longitudinal study for 5 years, with cut-off points at 2 and 5 years, including 26 RRMS patients treated with GA for at least 6 months. A total of 6 miRNAs from a previous study (miR-9.5p, miR-126...
October 12, 2023: Biomedicines
#29
JOURNAL ARTICLE
Sean A Freeman, Bruno Lemarchant, Tifanie Alberto, Julie Boucher, Olivier Outteryck, Myriam Labalette, Stéphanie Rogeau, Sylvain Dubucquoi, Hélène Zéphir
Few studies have investigated sustained B-cell depletion after long-term intravenous (IV) anti-CD20 B-cell depleting therapy (BCDT) in multiple sclerosis (MS) with respect to strict and/or minimal disease activity. The main objective of this study was to investigate how sustained B-cell depletion after BCDT influences clinical and radiological stability as defined by "no evidence of disease activity" (NEDA-3) and "minimal evidence of disease activity" (MEDA) status in MS patients at 12 and 18 months. Furthermore, we assessed the frequency of serious adverse events (SAE), and the influence of prior lymphocytopenia-inducing treatment (LIT) on lymphocyte subset counts and gammaglobulins in MS patients receiving long-term BCDT...
October 26, 2023: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
#30
JOURNAL ARTICLE
José E Meca-Lallana, José M Prieto González, Ana B Caminero Rodríguez, Javier Olascoaga Urtaza, Ana M Alonso, Eduardo Durán Ferreras, Raúl Espinosa, Julio Dotor, Mercedes Romera, Adrián Ares Luque, Domingo Pérez Ruiz, Carmen Calles, Miguel A Hernández, Miguel Hervás García, Amelia Mendoza Rodríguez, Yasmina Berdei Montero, Nieves Téllez, Nicolás Herrera Varó, Javier Sotoca, Silvia Presas-Rodríguez, Luis A Querol Gutierrez, Mariona Hervás Pujol, Jordi Batlle Nadal, Gisela Martín Ozaeta, Laura Gubieras Lillo, Sergio Martínez Yélamos, Lluís Ramió-Torrentà, Javier Mallada Frechin, Antonio Belenguer Benavides, Francisco Gascón-Giménez, Bonaventura Casanova, Lamberto Landete Pascual, Leticia Berenguer, Laura Navarro, Montserrat Gómez Gutierrez, Carmen Durán, Ana Rodríguez Regal, Elena Álvarez, Daniel A García-Estévez, Ana M López Real, Miguel A Llaneza González, María E Marzo Sola, José L Sánchez-Menoyo, Agustín Oterino, Ramón Villaverde González, Tamara Castillo-Triviño, Amaya Álvarez de Arcaya, Cristina Llarena
INTRODUCTION: Teriflunomide is a once-daily oral immunomodulator approved for relapsing forms of multiple sclerosis (MS) or relapsing-remitting multiple sclerosis (RRMS; depending on the local label), based on extensive evidence from clinical trials and a real-world setting on efficacy, tolerability and patient-reported benefits. The TERICARE study assessed the impact of teriflunomide treatment over 2 years on health-related quality of life (HRQoL) and some of the most common and disabling symptoms of MS, such as fatigue and depression...
October 20, 2023: Neurology and Therapy
#31
JOURNAL ARTICLE
Michael Barnett, Dongang Wang, Heidi Beadnall, Antje Bischof, David Brunacci, Helmut Butzkueven, J William L Brown, Mariano Cabezas, Tilak Das, Tej Dugal, Daniel Guilfoyle, Alexander Klistorner, Stephen Krieger, Kain Kyle, Linda Ly, Lynette Masters, Andy Shieh, Zihao Tang, Anneke van der Walt, Kayla Ward, Heinz Wiendl, Geng Zhan, Robert Zivadinov, Yael Barnett, Chenyu Wang
Modern management of MS targets No Evidence of Disease Activity (NEDA): no clinical relapses, no magnetic resonance imaging (MRI) disease activity and no disability worsening. While MRI is the principal tool available to neurologists for monitoring clinically silent MS disease activity and, where appropriate, escalating treatment, standard radiology reports are qualitative and may be insensitive to the development of new or enlarging lesions. Existing quantitative neuroimaging tools lack adequate clinical validation...
October 19, 2023: NPJ Digital Medicine
#32
JOURNAL ARTICLE
María Inmaculada Domínguez-Mozo, Inés González-Suárez, Luisa María Villar, Lucienne Costa-Frossard, Noelia Villarrubia, Yolanda Aladro, Belén Pilo, Xavier Montalbán, Manuel Comabella, Ignacio Casanova-Peño, María Luisa Martínez-Ginés, Jose Manuel García-Domínguez, María Ángel García-Martínez, Rafael Arroyo, Roberto Álvarez-Lafuente
BACKGROUND: Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6) have been associated with multiple sclerosis (MS). Teriflunomide is an oral disease-modifying therapy approved for treatment of relapsing forms of MS. In the preclinical Theiler's murine encephalitis virus model of MS, the drug demonstrated an increased rate of viral clearance versus the vehicle placebo. Furthermore, teriflunomide inhibits lytic EBV infection in vitro . OBJECTIVE: 1. To evaluate the humoral response against EBV and HHV-6 prior to teriflunomide treatment and 6 months later...
2023: Frontiers in Immunology
#33
JOURNAL ARTICLE
Esteban Alejandro Gomez-Gaitan, Yessica Eleanet Garcia-Ortega, Ana Miriam Saldaña-Cruz, Betsabe Contreras-Haro, Jorge Ivan Gamez-Nava, Emilio Edsaul Perez-Guerrero, Cesar Arturo Nava-Valdivia, Sergio Gallardo-Moya, Alejandra Martinez-Hernandez, Laura Gonzalez Lopez, Blanca Esthela Rios-Gonzalez, Jazmin Marquez-Pedroza, Miriam Mendez-Del Villar, Yussef Esparza-Guerrero, Alejandra Villagomez-Vega, Miguel Angel Macias Islas
Multiple sclerosis (MS) is a chronic and demyelinating disease with an autoimmune origin, which leads to neurodegeneration and progressive disability. Approximately 30 to 50% of patients do not respond optimally to disease-modifying therapies (DMTs), and therapeutic response may be influenced by genetic factors such as genetic variants. Therefore, our study aimed to investigate the association of the HLA-DRB1*0403 genetic variant and therapeutic response to DMTs in MS. We included 105 patients with MS diagnosis...
September 27, 2023: International Journal of Molecular Sciences
#34
REVIEW
Scott D Newsome, Cherie Binns, Ulrike W Kaunzner, Seth Morgan, June Halper
The emergence of high-efficacy therapies for multiple sclerosis (MS), which target inflammation more effectively than traditional disease-modifying therapies, has led to a shift in MS management towards achieving the outcome assessment known as no evidence of disease activity (NEDA). The most common NEDA definition, termed NEDA-3, is a composite of three related measures of disease activity: no clinical relapses, no disability progression, and no radiological activity. NEDA has been frequently used as a composite endpoint in clinical trials, but there is growing interest in its use as an assessment tool to help patients and healthcare professionals navigate treatment decisions in the clinic...
October 11, 2023: Neurology and Therapy
#35
JOURNAL ARTICLE
Torge Rempe, Aisha Elfasi, Elsa Rodriguez, Matthew Vasquez, Jennifer Graves, Revere Kinkel
BACKGROUND: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody used in treatment of multiple sclerosis. The standard dosing (SD) regimen consists of OCR maintenance infusions every 6 months. In B-cell repopulation-guided extended interval dosing (EID), repeat infusions are delayed until there is evidence for B-cell repopulation. OBJECTIVES: To compare frequencies of 'no evidence of disease activity' (NEDA-3) and immunoglobulin G (hypo-IgG; <600 mg/dL) and M (hypo-IgM; <40 mg/dL) deficiencies in persons with multiple sclerosis (PwMS) treated with OCR B-cell repopulation-guided EID versus SD...
November 2023: Multiple Sclerosis and related Disorders
#36
JOURNAL ARTICLE
Sofia Sandgren, Lenka Novakova, Anna Nordin, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke
BACKGROUND: Alemtuzumab (ALZ) is a pulsed immune reconstitution therapy for multiple sclerosis (MS). OBJECTIVE: To assess basic characteristics, therapeutic effects, and prognostic biomarkers on clinical and imaging parameters of disease activity for relapsing-remitting MS (RRMS) patients selected for ALZ, in a real-world long-term setting. METHODS: Fifty-one RRMS patients [female = 31; mean age 36 (standard deviation 7.1) years; median expanded disability status scale (EDSS) 2 (interquartile range (IQR) 1...
2023: Frontiers in Neurology
#37
JOURNAL ARTICLE
Filipe Palavra, Diogo Silva, Catarina Fernandes, Ricardo Faustino, Mónica Vasconcelos, Cristina Pereira, Carmen Costa, Joana Afonso Ribeiro, Joana Amaral, Conceição Robalo
INTRODUCTION: Multiple sclerosis (MS) is an inflammatory and demyelinating disorder of central nervous system that can be diagnosed in pediatric age (<18 years) in 3-5% of the cases. This early onset is associated with higher relapse rates and earlier progression to neurological disability. By using NEDA-3 (No Evidence of Disease Activity-3) criteria, we aimed to identify clinical predictors associated with absence of disease activity and control of disease progression 12 months after the diagnosis, in a cohort of pediatric-onset MS (POMS) patients regularly followed-up in our center...
2023: Frontiers in Neuroscience
#38
JOURNAL ARTICLE
V Bazzurri, A Fiore, E Curti, E Tsantes, A Franceschini, F Granella
BACKGROUND: No evidence of disease activity (NEDA) is becoming a gold standard in the evaluation of disease modifying therapies (DMT) in relapsing-remitting multiple sclerosis (RRMS). NEDA-3 status is the absence of relapses, new activity on brain MRI, and disability progression. NEDA-4 meets all NEDA-3 criteria plus lack of brain atrophy. OBJECTIVE: Aim of this study was to investigate the prevalence of two-year NEDA-3, NEDA-4, six-month delayed NEDA-3 (6mdNEDA-3), and six-month delayed NEDA-4 (6mdNEDA-4) in a cohort of patients with RRMS...
November 2023: Multiple Sclerosis and related Disorders
#39
JOURNAL ARTICLE
Raed Alroughani, Malak AlMojel, Jasem Al-Hashel, Samar Farouk Ahmed
BACKGROUND: Ocrelizumab is a humanized anti-CD20 antibody that has been approved for the treatment of patients with multiple sclerosis (MS). Real-world data in the Middle East is very limited. OBJECTIVES: To describe the effectiveness and safety of ocrelizumab treatment in MS patients in a real clinical setting. METHODS: This is an observational, registry-based study. MS patients who were treated with ocrelizumab and completed at least one-year follow-up post-treatment were included...
August 18, 2023: Multiple Sclerosis and related Disorders
#40
JOURNAL ARTICLE
Chiara Zilli, Pietro Scribani Rossi, Arianna Di Stadio, Mariangela Fratino, Giada Giuliani, Rosanna Annecca, Gaetano Russo, Vittorio Di Piero, Marta Altieri
INTRODUCTION: Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the CNS with an autoimmune pathogenesis. Over the years, numerous disease-modifying therapies (DMTs) have proven effective in disease control; to date, there is a need to identify a personalized treatment effective in ensuring disease-free status or no evidence of disease activity (NEDA). OBJECTIVE: identify clinical, demographic and treatment approach characteristics that affect the maintenance of NEDA-3 and the occurrence of clinical relapses during a 6-years follow-up...
2023: Frontiers in Neurology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
